Skip to main content
TipRanks
Go Ultimate75% OFF

Samuel Saks Insider Profile

4 Followers

Samuel Saks, CMO at Protagonist Therapeutics, holds 14.00K shares in Protagonist Therapeutics (Ticker: PTGX), holds 214.19K shares in PDL BioPharma (Ticker: PDLI), holds 6.61K shares in Tonix Pharma (Ticker: TNXP).

Samuel Saks's Trading History

PTGX
Protagonist Therapeutics
Feb 26, 2021CMOUninformative Buy―$1.75M
PDLI
PDL BioPharma
Jun 12, 2018―Uninformative Buy150.00K$529.05K
TNXP
Tonix Pharma
Mar 09, 2018DirectorUninformative Buy5.44K$19.02K
ASRT
Assertio Therapeutics
May 13, 2016―Uninformative Sell12.86K$68.08K
ASPX
Auspex Pharma
May 05, 2015―Uninformative Sell――
JAZZ
Jazz Pharmaceuticals
―CEO, Director―$86.05M

You May Also Like

Samuel Saks insider profile FAQ

What is the percentage of profitable transactions made by Samuel Saks?
The percentage of profitable transactions made by Samuel Saks is 33%.
What is the average return per transaction made by Samuel Saks?
The average return per transaction made by Samuel Saks is 9.30%.
What stocks does Samuel Saks hold?
Samuel Saks holds: PTGX, ASPX, TNXP, PDLI, ASRT, JAZZ stocks.
What was Samuel Saks's most profitable transaction?
Samuel Saks’s most profitable transaction was an Informative Buy of ASPX stock on February 12, 2014. The return on the trade was 183.70%.
What is Samuel Saks's role in Protagonist Therapeutics?
Samuel Saks's role in Protagonist Therapeutics is CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.